This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Aiura, K
Right arrow Articles by Dinarello, C A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Aiura, K
Right arrow Articles by Dinarello, C A

 Previous Article  |  Next Article 

Infect Immun. 1993 August; 61(8): 3342-3350

Interleukin-1 (IL-1) receptor antagonist prevents Staphylococcus epidermidis-induced hypotension and reduces circulating levels of tumor necrosis factor and IL-1 beta in rabbits.

K Aiura, J A Gelfand, J F Burke, R C Thompson and C A Dinarello

Department of Medicine, Tufts University and New England Medical Center Hospital, Boston, Massachusetts 02111.

ABSTRACT

Similar to shock in gram-negative sepsis, shock from gram-positive organisms is mediated, in part, by tumor necrosis factor (TNF) and interleukin-1 (IL-1). In the present study, rabbits were infused with IL-1 receptor antagonist (IL-1ra) prior to and during Staphylococcus epidermidis-induced hypotension. After injection of bacteria, a maximal fall in mean arterial pressure to -42% below baseline occurred at 200 min in vehicle-treated animals compared with a nonsignificant decrease of only 7% in the IL-1ra-treated group (P < 0.01, vehicle versus IL-1ra). A similar attenuation was observed in the fall in systemic vascular resistance (P < 0.05). After the injection of S. epidermidis, TNF levels rose to a peak elevation of 475 +/- 160 U/ml in vehicle-treated rabbits, but in rabbits receiving IL-1ra, maximal TNF levels rose only to 85 +/- 23 U/ml (P < 0.01). Plasma IL-1 beta reached maximal concentrations at 180 min of 364 +/- 71 pg/ml in vehicle-treated animals but only 145 +/- 12 pg/ml in rabbits given IL-1ra (P < 0.05). The reductions in TNF and IL-1 were not due to interference by IL-1ra in the respective assays. In vitro, IL-1ra inhibited S. epidermidis-induced TNF from mononuclear cells by 31% +/- 11%, from spleen cells by 17% +/- 4% (P < 0.05), and from whole blood by 42% +/- 17%. Despite the near reversal of the fall in mean arterial pressure and systemic vascular resistance in IL-1ra-treated rabbits, leukopenia and thrombocytopenia were unaffected. These results demonstrate that IL-1ra blocks shock-like hemodynamic parameters and reduces circulating IL-1 and TNF levels in a model of gram-positive sepsis.

Infect Immun. 1993 August; 61(8): 3342-3350




This article has been cited by other articles:

  • Faubel, S., Lewis, E. C., Reznikov, L., Ljubanovic, D., Hoke, T. S., Somerset, H., Oh, D.-J., Lu, L., Klein, C. L., Dinarello, C. A., Edelstein, C. L. (2007). Cisplatin-Induced Acute Renal Failure Is Associated with an Increase in the Cytokines Interleukin (IL)-1beta, IL-18, IL-6, and Neutrophil Infiltration in the Kidney. J. Pharmacol. Exp. Ther. 322: 8-15 [Abstract] [Full Text]  
  • Wang, W., Faubel, S., Ljubanovic, D., Mitra, A., Falk, S. A., Kim, J., Tao, Y., Soloviev, A., Reznikov, L. L., Dinarello, C. A., Schrier, R. W., Edelstein, C. L. (2005). Endotoxemic acute renal failure is attenuated in caspase-1-deficient mice. Am. J. Physiol. Renal Physiol. 288: F997-F1004 [Abstract] [Full Text]  
  • Dinarello, C. A. (2004). Review: Infection, fever, and exogenous and endogenous pyrogens: some concepts have changed. Innate Immunity 10: 201-222 [Abstract]  
  • Dinarello, C. A., Abraham, E. (2002). Does Blocking Cytokines in Sepsis Work?. Am. J. Respir. Crit. Care Med. 166: 1156-1157 [Full Text]  
  • Stuyt, R. J. L., Netea, M. G., Kim, S.-H., Novick, D., Rubinstein, M., Kullberg, B.-J., Van der Meer, J. W. M., Dinarello, C. A. (2001). Differential Roles of Interleukin-18 (IL-18) and IL-12 for Induction of Gamma Interferon by Staphylococcal Cell Wall Components and Superantigens. Infect. Immun. 69: 5025-5030 [Abstract] [Full Text]  
  • Opal, S. M., DePalo, V. A. (2000). Anti-Inflammatory Cytokines. Chest 117: 1162-1172 [Abstract] [Full Text]  
  • Petrovic, N., Kane, C. M., Sigmund, C. D., Gross, K. W. (1997). Downregulation of Renin Gene Expression by Interleukin-1. Hypertension 30: 230-235 [Abstract] [Full Text]  
  • Dinarello, C.A. (1995). Blocking interleukin-1 in sepsis. Innate Immunity 2: 157-162 [Abstract]  
  • Fisher, C.J. JR (1995). Can second-generation versions of existing therapeutics be successful in clinical trials of sepsis?. Innate Immunity 2: 227-232 [Abstract]  
  • Fisher, C. J. Jr, Dhainaut, J.-F. A., Opal, S. M., Pribble, J. P., Balk, R. A., Slotman, G. J., Iberti, T. J., Rackow, E. C., Shapiro, M. J., Greenman, R. L., Reines, H. D., Shelly, M. P., Thompson, B. W., LaBrecque, J. F., Catalano, M. A., Knaus, W. A., Sadoff, J. C., the Phase III rhIL-1ra Sepsis Syndrome Study Group, , The Phase III rhIL-1ra Sepsis Syndrome Study Group, , Astiz, M., Rackow, E. C., Carpati, C., Balk, R. A., Bone, R. C., Slotman, G. J., Friedman, B., Mure, A. J., Brathwaite, C., Shapiro, E., Melhorn, L., Shapiro, M. J., Taylor, R., Keegan, M., O'Brien, J., Greenman, R. L., Schein, R., Pena, M., Wasserlouf, M., Iberti, T. J., Oropello, J., Benjamin, E., DelGuidice, R., Emmanuel, G., Lie, T., Anderson, L., Marshall, J., De Majo, W., Rotstein, O., Foster, D., Abraham, E., Middleton, H., Perry, C., Levy, H., Fry, D. E., Simpson, S. Q., Crowell, R. E., Neidhart, M., Stevens, D., Coffman, T., Narasimhan, N., Merrick, D. K., Bergquist, W., Matzel, K. E., Huebler, M., Foulke, G. E., Albertson, T. E., Walby, W. F., Allen, R. P., Baughman, R., Hasselgren, P.-O., Fink, M. P., Favorito, F., Thompson, B. T., Corbin, R., Shellhorse, G. Y., Frazier, A., White, S., Garrard, C., A'Court, C., Storer, S., Gervich, D. H., Foshe, D., Brase, R., Bagdahn, A., Cooney, R., Smith, J. S. Jr, Martin, L. F., Vincent, J.-L., Friedman, G., Berlot, G., Fletcher, J. R., Williams, M. D., Wright, T. F., Johnson, S., Feild, C., Wolf, K., MacIntyre, N., Opal, S. M., Dubin, H. G., Durkin, M. R., Dubin, P. K., Staubach, K. H., Fein, A. M., Schulman, D. B., Niederman, M. S., Chalfin, D. B., van, P. A. M., Leeuwen, , Boermeester, M. A., Schneider, A. J., Bander, J., Imm, A., Bernard, G., Nelson, L., Stroud, M., Safcsak, K., Cerra, F., Rindal, J., Mann, H., Halpern, N., Silverstein, J., Alicea, M., Sibbald, W. J., Martin, C. M., Rutledge, F. S., Petti, K., Russell, J. A., Kruger, R., Drummond, A., Fisher, C. J. Jr, Lange, P., Seifert, T., Durocher, A., Tenaillon, A., Boiteau, R., Lherm, T., Lowry, S. F., Coyle, S. M., Barie, P. S., DeMaria, E., Reines, H. D., Snydman, D. R., Schwaitzberg, S. D., Nasraway, S. A. Jr, Grindlinger, J., Summer, W., de Boisblanc, B., Wahl, M., Alestig, K., Grossman, J., Maki, D., Paz, H. L., Weiner, M., Bihari, D., Campbell, D., Bleichner, G., Dahn, M. S., Lange, M. P., Hall, J., Pohlman, A., Wenzel, R. P., Grosserode, M., Costigan, M., Mileski, W., Weigelt, J., Yeston, N., Irizarry, C., Ross, J., Robbins, J., Shelly, M. P., Nightingale, P., Owen, K., Sandstedt, S., Berg, S., Simon, G. L., Seneff, M. G., Conry, K. M., Zimmerman, J. L., Dellinger, R. P., Johnston, R. Jr, Allee, P., Grande, P.-O., Myhre, E., Dhainaut, J.-F., Hamy, I., Mira, J.-P., Harmon, J., White, J., McKie, L., Silverman, H., Tuma, P., Bennett, D., Porter, J. C., Laurell, M. H., Jacobs, S., Ash, S., Clinical Evaluation Committee, , Fisher, C. J. Jr, Dhainaut, J.-F., Opal, S. M., Balk, R. A., Slotman, G. J., Iberti, T. J., Reines, H. D., Shelly, M. P., Sadoff, J. C., Pribble, J. P., Stiles, D. M., Thompson, B. W., Prior, M. J., Knatterud, G., Terrin, M., Kufera, J., Wilkens, P., Ra, K., Monroe, L., Safety and Efficacy Monitoring Committee, , Sprung, C., Hamilton, C. M., Matthay, R., McCabe, W., Tonascia, J., Wiedeman, H., Wittes, J., Thompson, B. W., Knatterud, G., Pribble, J. P., Stiles, D. M., LaBrecque, J. F., Catalano, M. A., Campion, G. V., Croft, C. R., Lustick, R., Lookabaugh, J., Gordon, G. S., Noe, L., Bloedow, D., Christopher, S. G., Brannon, D., Kush, R., Ng, D., Moore, E., Bazemore, K., Galvan, M., Knaus, W. A., Wagner, D., Harrell, F., Stablein, D. (1994). Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial. JAMA 271: 1836-1843 [Abstract]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»